INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
Public company

INCYINCYTE CORP

CIK 0000879169

EDGAR filingsOpen in network
Disclosed transactions53
Buys / sells0 / 17
Max Insider Score36
Connections16with evidence

INCY · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
8
HL
Heeson LeeEVP, Head of Incyte Intl
INCYINCYTE CORP
Tax withholding
F$54K
463 sh
Oct 1, 2026Oct 5, 2026
traded Oct 1, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • ← Insider ofevidence
    Gardner David HEVP, Chief Strategy Officer · Sep 24, 2026
  • ← Insider ofevidence
    Basi Ramitpal KEVP, Human Resources · Aug 27, 2026
  • ← Lobbied forevidence
    AVENUE SOLUTIONSLDA Q1 2026 first quarter · Health issues, Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    TIBER CREEK GROUPLDA Q2 2026 second quarter · Medicare/Medicaid, Health issues · Aug 26, 2026
16
GH
Gardner David HEVP, Chief Strategy Officer
INCYINCYTE CORP
Tax withholding
F
$117K
920 sh
Sep 22, 2026
Sep 24, 2026
traded Sep 22, 2026
+2d
SEC FORM 4

Evidence

12
BK
Basi Ramitpal KEVP, Human Resources
INCYINCYTE CORP
Tax withholding
F$65K
504 sh
Aug 25, 2026Aug 27, 2026
traded Aug 25, 2026
+2dSEC FORM 4

Evidence

0
MA
Mayes Patrick AEVP & Chief Scientific Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M$235K
2,207 sh
Aug 5, 2026Aug 7, 2026
traded Aug 5, 2026
+2dSEC FORM 4

Evidence

0
MA
Mayes Patrick AEVP & Chief Scientific Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M—
2,207 sh
Aug 5, 2026Aug 7, 2026
traded Aug 5, 2026
+2dSEC FORM 4

Evidence

7
MA
Mayes Patrick AEVP & Chief Scientific Officer
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$274K
2,207 sh
Aug 5, 2026Aug 7, 2026
traded Aug 5, 2026
+2dSEC FORM 4

Evidence

11
MA
Mayes Patrick AEVP & Chief Scientific Officer
INCYINCYTE CORP
Tax withholding
F$41K
350 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

11
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Tax withholding
F$56K
477 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

2
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M$221K
2,639 sh
Jun 4, 2026Jun 8, 2026
traded Jun 4, 2026
+4dSEC FORM 4

Evidence

11
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$264K
2,639 sh
Jun 4, 2026Jun 8, 2026
traded Jun 4, 2026
+4dSEC FORM 4

Evidence

0
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M—
2,639 sh
Jun 4, 2026Jun 8, 2026
traded Jun 4, 2026
+4dSEC FORM 4

Evidence

8
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$200K
2,051 sh
May 26, 2026May 28, 2026
traded May 26, 2026
+2dSEC FORM 4

Evidence

9
TM
Trotta MatteoEVP, GM, Dermatology US
INCYINCYTE CORP
Tax withholding
F$50K
537 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

5
HL
Heeson LeeEVP, Head of Incyte Intl
INCYINCYTE CORP
Tax withholding
F$11K
111 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

11
MA
Mayes Patrick AEVP & Chief Scientific Officer
INCYINCYTE CORP
Grant or award
A—
4,218 sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

19
HL
Heeson LeeEVP, Head of Incyte Intl
INCYINCYTE CORP
Grant or award
A—
8,911 sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

15
TM
Trotta MatteoEVP, GM, Dermatology US
INCYINCYTE CORP
Grant or award
A—
8,542 sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

11
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Grant or award
A—
2,425 sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

19
MJ
Morrissey Michael JamesEVP, Head of Tech. Operations
INCYINCYTE CORP
Grant or award
A—
7,426 sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

5
MJ
Morrissey Michael JamesEVP, Head of Tech. Operations
INCYINCYTE CORP
Tax withholding
F$44K
429 sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC FORM 4

Evidence

11
IK
Issa Mohamed KhairieEVP, Head of US Oncology
INCYINCYTE CORP
Grant or award
A—
14.2K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

18
IK
Issa Mohamed KhairieEVP, Head of US Oncology
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$1.18M
10.9K sh
Jan 7, 2026Jan 8, 2026
traded Jan 7, 2026
+1dSEC FORM 4

Evidence

9
IK
Issa Mohamed KhairieEVP, Head of US Oncology
INCYINCYTE CORP
Tax withholding · 10b5-1 plan
F$881K
8,264 sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

0
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M—
1,044 sh
Dec 19, 2025Dec 22, 2025
traded Dec 19, 2025
+3dSEC FORM 4

Evidence

14
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$59K
600 sh
Dec 18, 2025Dec 22, 2025
traded Dec 18, 2025
+4dSEC FORM 4

Evidence

0
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M$100K
1,044 sh
Dec 19, 2025Dec 22, 2025
traded Dec 19, 2025
+3dSEC FORM 4

Evidence

2
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M$166K
1,730 sh
Dec 19, 2025Dec 22, 2025
traded Dec 19, 2025
+3dSEC FORM 4

Evidence

21
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$277K
2,774 sh
Dec 19, 2025Dec 22, 2025
traded Dec 19, 2025
+3dSEC FORM 4

Evidence

0
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M—
1,730 sh
Dec 19, 2025Dec 22, 2025
traded Dec 19, 2025
+3dSEC FORM 4

Evidence

18
MJ
Morrissey Michael JamesEVP, Head of Tech. Operations
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$81K
833 sh
Dec 16, 2025Dec 18, 2025
traded Dec 16, 2025
+2dSEC FORM 4

Evidence

36
MJ
Morrissey Michael JamesEVP, Head of Tech. Operations
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$5.17M
53.2K sh
Dec 16, 2025Dec 18, 2025
traded Dec 16, 2025
+2dSEC FORM 4

Evidence

21
MJ
Morrissey Michael JamesEVP, Head of Tech. Operations
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$420K
4,323 sh
Dec 17, 2025Dec 18, 2025
traded Dec 17, 2025
+1dSEC FORM 4

Evidence

25
MA
Mayes Patrick AEVP & Chief Scientific Officer
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$531K
5,553 sh
Dec 10, 2025Dec 12, 2025
traded Dec 10, 2025
+2dSEC FORM 4

Evidence

11
MA
Mayes Patrick AEVP & Chief Scientific Officer
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$24K
255 sh
Dec 11, 2025Dec 12, 2025
traded Dec 11, 2025
+1dSEC FORM 4

Evidence

9
HA
Hoffman Richard A.EVP & General Counsel
INCYINCYTE CORP
Grant or award
A—
43.3K sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

9
HA
Hoffman Richard A.EVP & General Counsel
INCYINCYTE CORP
Grant or award
A—
9,466 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

9
HA
Hoffman Richard A.EVP & General Counsel
INCYINCYTE CORP
Grant or award
A—
23.7K sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

10
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$17K
169 sh
Nov 21, 2025Nov 25, 2025
traded Nov 21, 2025
+4dSEC FORM 4

Evidence

9
TT
Tray ThomasPrincipal Accounting Officer
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$62K
600 sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

0
DA
Denton Sheila A.EVP & General Counsel
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M—
278 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

16
DA
Denton Sheila A.EVP & General Counsel
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$29K
278 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

0
DA
Denton Sheila A.EVP & General Counsel
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M$18K
278 sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

5
SH
Stein Steven HEVP & Chief Medical Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M$287K
2,995 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

2
SH
Stein Steven HEVP & Chief Medical Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M$100K
1,194 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

21
SH
Stein Steven HEVP & Chief Medical Officer
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$535K
5,233 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

0
SH
Stein Steven HEVP & Chief Medical Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M—
2,995 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

0
SH
Stein Steven HEVP & Chief Medical Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M—
1,044 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

0
SH
Stein Steven HEVP & Chief Medical Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M—
1,194 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

2
SH
Stein Steven HEVP & Chief Medical Officer
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M$100K
1,044 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

18
DA
Denton Sheila A.EVP & General Counsel
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$61K
598 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

0
DA
Denton Sheila A.EVP & General Counsel
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M—
598 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

0
DA
Denton Sheila A.EVP & General Counsel
INCYINCYTE CORP
Option exercise · 10b5-1 plan
M$35K
598 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

25
HL
Heeson LeeEVP, Head of Incyte Intl
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$289K
3,074 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

  • ← Lobbied forevidence
    LMH STRATEGIC SOLUTIONSLDA Q2 2026 second quarter · Health issues, Pharmacy · Aug 26, 2026
  • ← Lobbied forevidence
    W STRATEGIES, LLCLDA Q2 2026 second quarter · Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    CHECKMATE GOVERNMENT RELATIONSLDA Q2 2026 second quarter · Medicare/Medicaid · Aug 26, 2026
  • ← Insider ofevidence
    Trotta MatteoEVP, GM, Dermatology US · Jan 21, 2026
  • ← Insider ofevidence
    Issa Mohamed KhairieEVP, Head of US Oncology · Jan 8, 2026
  • ← Insider ofevidence
    Morrissey Michael JamesEVP, Head of Tech. Operations · Dec 18, 2025
  • ← Insider ofevidence
    Mayes Patrick AEVP & Chief Scientific Officer · Dec 12, 2025
  • ← Insider ofevidence
    Hoffman Richard A.EVP & General Counsel · Dec 3, 2025
  • ← Insider ofevidence
    Tray ThomasPrincipal Accounting Officer · Nov 25, 2025
  • ← Insider ofevidence
    Stein Steven HEVP & Chief Medical Officer · Nov 7, 2025
  • ← Insider ofevidence
    Denton Sheila A.EVP & General Counsel · Nov 6, 2025
  • ← Insider ofevidence
    Heeson LeeEVP, Head of Incyte Intl · Nov 5, 2025

    • Lobbying

    $1.23M reported · de-duplicated
    2026 Q2 $750K in-house2026 Q1 $480K in-house
    • LMH STRATEGIC SOLUTIONS$50K2026 Q1 · posted Aug 26, 2026 · Pharmacy, Health issues
    • TIBER CREEK GROUP$80K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid
    • TIBER CREEK GROUP$80K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues
    • CHECKMATE GOVERNMENT RELATIONS$110K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid
    • In-house report$480K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid
    • AVENUE SOLUTIONS$60K2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
    • W STRATEGIES, LLC$60K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid
    • CHECKMATE GOVERNMENT RELATIONS$110K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid
    • AVENUE SOLUTIONS$60K2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
    • LMH STRATEGIC SOLUTIONS$50K2026 Q2 · posted Aug 26, 2026 · Health issues, Pharmacy
    • W STRATEGIES, LLC$60K2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
    • In-house report$750K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.